key: cord-0705564-fleibepf authors: Zhang, Naru; Li, Chaoqun; Hu, Yue; Li, Kangchen; Liang, Jintian; Wang, Lili; Du, Lanying; Jiang, Shibo title: Current development of COVID-19 diagnostics, vaccines and therapeutics date: 2020-05-06 journal: Microbes Infect DOI: 10.1016/j.micinf.2020.05.001 sha: 5de6b4de529c8d5c4b015286f3f2ff85f521733f doc_id: 705564 cord_uid: fleibepf Abstract A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and control further outbreaks of SARS-CoV-2 infection. In late December 2019, a pneumonia of unknown etiology emerged in Wuhan City, 27 Hubei Province, China. Patients presenting with acute respiratory failure were seen in 28 the ER and then admitted to ICU facilities for further treatment [1] . The causative . Although the mortality rate of SARS-CoV-2 is lower than that of 50 MERS-CoV and SARS-CoV, its transmissibility (median R 0 : 5.7) is much higher than 51 that of either MERS-CoV (R 0 : <1) or SARS-CoV (R 0 : 3) [ Up to now, SARS-CoV-2 has been detected from clinical specimens analyzed by under development by several organizations through international collaborations [32] . The pulmonary surfactant-biomimetic nanoparticles used to potentiate heterosubtypic 152 influenza immunity can be used as adjuvant to enhance the immunogenicity of 153 SARS-CoV-2 subunit vaccines [33] . roxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or). Another interesting strategy is to use convalescent plasma (CP) as treatment, but it 238 should be noted that CP should be collected within two weeks after recovery to ensure 239 a high neutralization antibody titer [50] . It was reported that SARS-CoV-2 isolated Clinical features of 314 patients infected with 2019 novel coronavirus in Wuhan, China A distinct name is 317 needed for the new coronavirus Early transmission 319 dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl 320 Potential interventions for novel coronavirus in China: A 322 systematic review Epidemiology, genetic 324 recombination, and pathogenesis of coronaviruses Middle East respiratory syndrome coronavirus fusion inhibitor Subunit vaccines against emerging 374 pathogenic human coronaviruses An emerging coronavirus causing pneumonia outbreak 376 in Wuhan, China: calling for developing therapeutic and prophylactic 377 strategies Inovio Collaborating With Beijing Advaccine To Advance 379 INO-4800 Vaccine Against New Coronavirus In China Partner-with-CEPI-in-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19 DNA-Vaccine-in-South-Korea/default.aspx. Accessed 22 Kaiser 384 Permanente launches first coronavirus vaccine trial MERS-CoV spike protein: a key 388 target for antivirals MERS-CoV spike protein: Targets 390 for vaccines and therapeutics Introduction of neutralizing 392 immunogenicity index to the rational design of MERS coronavirus subunit 393 vaccines The spike protein of 395 Clover initiates development of recombinant 398 subunit-trimer vaccine for Wuhan coronavirus (2019-nCoV) Characterization of the 400 receptor-binding domain (RBD) of 2019 novel coronavirus: implication for 401 development of RBD protein as a viral attachment inhibitor and vaccine The SARS-CoV-2 vaccine 404 pipeline: an overview Pulmonary 406 surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza 407 immunity China coronavirus: Hong Kong researchers have already developed 409 vaccine but need time to test it, expert reveals Codagenix raises $20 million for a new flu vaccine and other 413 therapies The COVID-19 vaccine development landscape. Nat Rev Drug 418 Discov 2020 Accessed 28 Partner with CEPI in Phase 1/2 Clinical Trial of 423 INOVIO's COVID-19 DNA Vaccine in South Korea Partner-with-CEPI-in-Phase-12-Clinical-Trial-of-INOVIOs 426 -COVID-19-DNA-Vaccine-in-South-Korea/default.aspx SARS-CoV-2 vaccines: status report A trial of 431 lopinavir-ritonavir in adults hospitalized with severe COVID-19 Case of the index 434 patient who caused tertiary transmission of COVID-19 infection in Korea: the 435 application of lopinavir/ritonavir for the treatment of COVID-19 infected 436 pneumonia monitored by quantitative RT-PCR Discovering drugs to treat coronavirus disease 2019 439 (COVID-19) A randomized, controlled trial of Ebola virus disease therapeutics Remdesivir and 444 chloroquine effectively inhibit the recently emerged novel coronavirus 445 (2019-nCoV) in vitro First case of 2019 novel coronavirus in the United States Effects of 450 chloroquine on viral infections: an old drug against today's diseases? Breakthrough: Chloroquine phosphate has shown 453 apparent efficacy in treatment of COVID-19 associated pneumonia in clinical 454 studies Hydroxychloroquine, a 456 less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 457 infection in vitro Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of 460 23 an open-label non-randomized clinical trial The epidemiology, diagnosis 463 and treatment of COVID-19 A pneumonia 465 outbreak associated with a new coronavirus of probable bat origin Treatment of 5 critically 468 ill patients with COVID-19 with convalescent plasma Effectiveness of convalescent 471 plasma therapy in severe COVID-19 patients Human polyclonal immunoglobulin G from transchromosomic bovines 474 inhibits MERS-CoV in vivo Potent binding of 2019 novel 476 coronavirus spike protein by a SARS coronavirus-specific human monoclonal 477 antibody Interaction between 479 heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: 480 implications for virus fusogenic mechanism and identification of fusion 481 inhibitors Inhibition of SARS-CoV-2 483 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion 484 inhibitor targeting its spike protein that harbors a high capacity to mediate 485 membrane fusion Fusion mechanism of 487 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein A 490 pan-coronavirus fusion inhibitor targeting the HR1 domain of human 491 coronavirus spike Emerging prophylaxis strategies against 493 COVID-19 Measures for diagnosing and treating 495 infections by a novel coronavirus responsible for a pneumonia outbreak 496 originating in Wuhan